Arcion Therapeutics Secures Funding For Trials
Thursday, January 10, 2008 5:39:00 AM PDT | VentureDeal Staff
LUTHERVILLE, MD -- Biotechnology company Arcion Therapeutics, Inc. said that it has raised its first round of institutional venture capital, securing $8.8 million in new investment.
Arcion is focused on developing treatments for severe pain associated with diabetic neuropathy, post-herpetic neuralgia and other forms of moderate to severe pain.
Investors leading the round were CMEA Ventures and InterWest Partners. The company said it would use the funding to continue development and trials for its topical clonidine gel.
Email Page | Print Page